Prostate cancer in men of African origin

Nature Reviews Urology

Volumn 13, Issue 2, 2016, Pages 99-107

  Mcginley, Kathleen F ^a   Tay, Kae Jack ^a   Moul, Judd W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MOLECULAR MARKER; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AFRICAN; BIOCHEMICAL RECURRENCE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CULTURAL ANTHROPOLOGY; CULTURAL SENSITIVITY; EDUCATIONAL STATUS; EPIGENETICS; GENETIC DIFFERENCE; GENETIC VARIABILITY; HEREDITY; HUMAN; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL STATUS; TREATMENT OUTCOME; AFRICAN AMERICAN; ETHNOLOGY; GENETIC VARIATION; GENETICS; INCIDENCE; PROSTATIC NEOPLASMS;

AFRICAN AMERICANS; GENETIC VARIATION; HUMANS; INCIDENCE; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 84957439807     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2015.298     Document Type: Review

References (124)

1. Fitzmaurice, C., et al The global burden of cancer 2013. JAMA Oncol. 1, 505-527 (2015
2. Odedina, F. T., et al. Prostate cancer disparities in black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect. Agent. Cancer 4, S2 (2009
3. Resnick, M. J., et al. Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy?. Urology 73, 620-623 (2009
4. Juang, R. M.,&Morrissette, N. A. Africa and the Americas: Culture, Politics, and History: a Multidisciplinary Encyclopedia (ABC-CLIO, 2008
5. Romero, F. R., Romero, A. W., Almeida, R. M.,&Tambara Filho, R. The prevalence of prostate cancer in Brazil is higher in black men than in white men: systematic review and meta-Analysis. Int. Braz. J. Urol. 38, 440-447 (2012
6. Rebbeck, T. R., et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer 560857 http://dx.doi.org/10.1155/2013/560857 (2013
7. Mahal, B. A., et al. Getting back to equal: the influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol. Oncol. 32, 1285-1291 (2014
8. Taksler, G. B., Keating, N. L.,&Cutler, D. M. Explaining racial differences in prostate cancer mortality. Cancer 118, 4280-4289 (2012
9. Morrison, B. F., Aiken, W. D.,&Mayhew, R. Current state of prostate cancer treatment in Jamaica. Ecancermedicalscience 8, 456 (2014
10. Tindall, E. A., et al. Clinical presentation of prostate cancer in black South Africans. Prostate 74, 880-891 (2014
11. Cowen, M. E., Kattan, M. W.,&Miles, B. J A national survey of attitudes regarding participation in prostate carcinoma testing. Cancer 78, 1952-1957 (1996
12. Lee, D. J., Consedine, N. S., Gonzalez, J. R.,&Spencer, B. A. Association of healthcare barriers with prostate-specific antigen screening among African-American and Afro-Caribbean men. Urology 80, 556-563 (2012
13. Sundi, D., et al. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?. J. Clin. Oncol. 31, 2991-2997 (2013
14. Tsivian, M., et al. African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center. Prostate Cancer Prostatic Dis. 16, 91-94 (2013
15. Yamoah, K., et al. African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. Urol. Oncol. 33, 70.e15-70.e22 (2014
16. Khani, F., et al. Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin. Cancer Res. 20, 4925-4934 (2014
17. Farrell, J., Petrovics, G., McLeod, D. G.,&Srivastava, S. Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int. J. Mol. Sci. 14, 15510-15531 (2013
18. Moul, J. W., et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 274, 1277-1281 (1995
19. Tiguert, R., et al. Racial differences and prognostic significance of tumor location in radical prostatectomy specimens. Prostate 37, 230-235 (1998
20. Sundi, D., et al. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. J. Urol. 191, 60-67 (2014
21. Mavropoulos, J. C., et al. Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men?. Urology 69, 1138-1142 (2007
22. Zhang, W., Sesterhenn, I. A., Connelly, R. R., Mostofi, F. K.,&Moul, J. W. Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J. Urol. 163, 131-136 (2000
23. Kubricht, W. S. 3rd, Williams, B. J., Whatley, T., Pinckard, P.,&Eastham, J. A. Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology 54, 1035-1038 (1999
24. Riegman, P. H., Vlietstra, R. J., van der Korput, J. A., Romijn, J. C.,&Trapman, J. Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem. Biophys. Res. Commun. 159, 95-102 (1989
25. Bensen, J. T., et al. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1, 536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate 73, 11-22 (2013
26. Bigler, S. A., Pound, C. R.,&Zhou, X A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer 239460 http://dx.doi.org/10.1155/2011/239460 (2011
27. Powell, I. J., Bock, C. H., Ruterbusch, J. J.,&Sakr, W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J. Urol. 183, 1792-1796 (2010
28. Evans, S., et al. Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study. Br. J. Cancer 102, 249-254 (2010
29. Ravery, V., et al. Prostate cancer characteristics in a multiracial community. Eur. Urol. 53, 533-538 (2008
30. Heyns, C. F., Fisher, M., Lecuona, A.,&van der Merwe, A. Prostate cancer among different racial groups in the Western Cape: presenting features and management. S. Afr. Med. J. 101, 267-270 (2011
31. Obiorah, C. C.,&Nwosu, S. O A histopathological study of carcinoma of the prostate in Port Harcourt, Nigeria. Niger. J. Clin. Pract. 14, 363-367 (2011
32. Kabore, F. A., Zango, B., Sanou, A., Yameogo, C.,&Kirakoya, B. Prostate cancer outcome in Burkina Faso. Infect. Agent Cancer 6, S6 (2011
33. Chu, L. W., et al. Prostate cancer incidence rates in Africa. Prostate Cancer 947870 http://dx.doi.org/10.1155/2011/947870 (2011
34. Patrick, A. Prostate-cancer screening in an Afro-Caribbean population: the Tobago Prostate Cancer Screening Study. BJU Int. 105, 745-746 (2010
35. Powell, I. J., Vigneau, F. D., Bock, C. H., Ruterbusch, J.,&Heilbrun, L. K. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol. Biomarkers Prev. 23, 1505-1511 (2014
36. Moyer, V. A. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120-134 (2012
37. Bhindi, B., et al. Impact of the U.S. Preventive Services Task Force recommend against prostate specifific antigen screening on prostate biopsy and cancer detection rates. J. Urol. 193, 1519-1524 (2015
38. Moul, J. W., et al. Re: early detection of prostate cancer: AUA guideline. J. Urol. 190, 1134-1137 (2013
39. Kazemi-Esfarjani, P., Trifiro, M. A.,&Pinsky, L. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n expanded neuronopathies. Hum. Mol. Genet. 4, 523-527 (1995
40. Chamberlain, N. L., Driver, E. D.,&Miesfeld, R. L. The length and location of CAG trinucleotide repeats in the androgen receptor N terminal domain affect transactivation function. Nucleic Acids Res. 22, 3181-3186 (1994
41. Beilin, J., Ball, E. M., Favaloro, J. M.,&Zajac, J. D. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J. Mol. Endocrinol. 25, 85-96 (2000
42. Giovannucci, E., et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl Acad. Sci. USA 94, 3320-3323 (1997
43. Sartor, O., Zheng, Q.,&Eastham, J. A. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 53, 378-380 (1999
44. Bennett, C. L., et al. Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J. Clin. Oncol. 20, 3599-3604 (2002
45. Price, D. K., et al. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. J. Urol. 184, 2297-2302 (2010
46. Gilligan, T., et al. Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin. Prostate Cancer 3, 98-103 (2004
47. Freedman, M. L., et al. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am. J. Hum. Genet. 76, 82-90 (2005
48. Lange, E. M., et al. The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Mens Health Study. J. Hum. Genet. 53, 220-226 (2008
49. Giovannucci, E. Is the androgen receptor CAG repeat length significant for prostate cancer?. Cancer Epidemiol. Biomarkers Prev. 11, 985-986 (2002
50. Gaston, K. E., et al. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J. Urol. 170, 990-993 (2003
51. Hendriksen, P. J. M., et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res. 66, 5012-5020 (2006
52. Zeegers, M. P., Jellema, A.,&Ostrer, H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-Analysis. Cancer 97, 1894-1903 (2003
53. Smith, J. R., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 274, 1371-1374 (1996
54. Cooney, K. A., et al. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J. Natl Cancer Inst. 89, 955-959 (1997
55. Choudhury, A. D., et al. The role of genetic markers in the management of prostate cancer. Eur. Urol. 62, 577-587 (2012
56. Haiman, C. A., et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat. Genet. 43, 570-573 (2011
57. Amann, J. M., et al. ETO, a target of t(8; 21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21, 6470-6483 (2001
58. Callen, D. F., et al. Co expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncol. Rep. 23, 1045-1052 (2010
59. Meyer, N., Kim, S. S.,&Penn, L. Z. The Oscar-worthy role of Myc in apoptosis. Semin. Cancer Biol. 16, 275-287 (2006
60. Huppi, K., Pitt, J. J., Wahlberg, B. M.,&Caplen, N. J. The 8q24 gene desert: an oasis of non-coding transcriptional activity. Front. Genet. 3, 69 (2012
61. Barnabas, N., Xu, L., Savera, A., Hou, Z.,&Barrack, E. R. Chromosome 8 markers of metastatic prostate cancer in African American men: gain of the MIR151 gene and loss of the NKX3 1 gene. Prostate 71, 857-871 (2011
62. Whitman, E. J., et al. Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol. Biomarkers Prev. 19, 1-8 (2010
63. Paris, P. L., et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev. 8, 901-905 (1999
64. Attard, G., Reid, A. H., Olmos, D.,&de Bono, J. S. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 69, 4937-4940 (2009
65. Taioli, E., et al. Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent. Prostate 73, 668-676 (2013
66. Jingwi, E. Y., et al. Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men. Anticancer Res. 35, 1549-1558 (2015
67. Grant, W. B.,&Peiris, A. N. Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and white Americans. Dermatoendocrinol. 4, 85-94 (2012
68. Harris, S. S. Vitamin D and African Americans. J. Nutr. 136, 1126-1129 (2006
69. Goh, L. K., et al. Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer. PLoS ONE e91666 http://dx.doi.org/10.1371/journal.pone.0091666 (2014
70. Kwabi-Addo, B., et al. Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin. Cancer Res. 16, 3539-3547 (2010
71. Wallace, T. A., et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68, 927-936 (2008
72. Hughes, L., Ruth, K., Rebbeck, T. R.,&Giri, V. N. Genetic variation in IL 16 miRNA target site and time to prostate cancer diagnosis in African-American men. Prostate Cancer Prostat. Dis. 16, 308-314 (2013
73. Trock, B. J. Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance. Curr. Opin. Urol. 24, 293-302 (2014
74. Magi-Galluzzi, C., et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71, 489-497 (2011
75. Mahal, B. A., et al. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology 84, 386-392 (2014
76. Zeliadt, S. B., Potosky, A. L., Etzioni, R., Ramsey, S. D.,&Penson, D. F. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 64, 1171-1176 (2004
77. Underwood, W., et al. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer 103, 538-545 (2005
78. Moses, K. A., Paciorek, A. T., Penson, D. F., Carroll, P. R.,&Master, V. A. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J. Clin. Oncol. 28, 1069-1074 (2010
79. Ziehr, D. R., et al. Income inequality and treatment of African American men with high-risk prostate cancer. Urol. Oncol. 33, 18.e7-18.e13 (2015
80. Faisal, F A., et al. Racial disparities in oncologic outcomes after radical prostatectomy: long-Term follow up. Urology 84, 1434-1441 (2014
81. Sanchez-Ortiz, R. F., et al. African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer 107, 75-82 (2006
82. Barocas, D. A., et al. Racial variation in the quality of surgical care for prostate cancer. J. Urol. 188, 1279-1285 (2012
83. Kouba, E., Hubbard, J. S., Moore, D., Wallen, E. M.,&Pruthi, R. S A prospective evaluation of the short-Term impact and recovery of health-related quality of life in men undergoing radical prostatectomy. BJU Int. 99, 72-76 (2007
84. Schroeck, F. R., et al. Satisfaction and regret after open retropubic or robot-Assisted laparoscopic radical prostatectomy. Eur. Urol. 54, 785-793 (2008
85. Sanda, M. G., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358, 1250-1261 (2008
86. Dinh, K. T., et al. Incidence and predictors of upgrading and up staging among 10, 000 contemporary patients with low risk prostate cancer. J. Urol. 194, 343-349 (2015
87. Kane, C. J., et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology 76, 695-700 (2010
88. Jalloh, M., Myers, F., Cowan, J. E., Carroll, P. R.,&Cooperberg, M. R. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics. Eur. Urol. 67, 451-457 (2015
89. Vora, A., et al. Predictors of Gleason score upgrading in a large African-American population. Int. Urol. Nephrol. 45, 1257-1262 (2013
90. Pietzak, E. J., et al. Impact of race on selecting appropriate patients for active surveillance with seemingly low-risk prostate cancer. Urology 85, 436-440 (2015
91. Iremashvili, V., Soloway, M. S., Rosenberg, D. L.,&Manoharan, M. Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J. Urol. 187, 1594-1599 (2012
92. Abern, M. R., et al. Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center. Prostate Cancer Prostat. Dis. 16, 85-90 (2013
93. Odom, B. D., et al. Active surveillance for low-risk prostate cancer in African American men: a multi-institutional experience. Urology 83, 364-368 (2014
94. Sundi, D., et al. Reclassification rates are higher among african american men than Caucasians on active surveillance. Urology 85, 155-160 (2015
95. Wilt, T. J., et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367, 203-213 (2012
96. Klabunde, C. N., Potosky, A. L., Harlan, L. C.,&Kramer, B. S. Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med. Care 36, 1337-1348 (1998
97. Nambudiri, V. E., et al. Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. Urology 79, 537-545 (2012
98. Moul, J. W., Douglas, T. H., McCarthy, W. F.,&McLeod, D. G. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J. Urol. 155, 1667-1673 (1996
99. Ritch, C. R., et al. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison. BJU Int. 111, E186-E190 (2013
100. Ogden, C. L., Carroll, M. D., Kit, B. K.,&Flegal, K. M. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311, 806-814 (2014
101. Turner, W. The index of the pelvic brim as a basis of classification. J. Anat. Physiol. 20, 125-143 (1885
102. Yamoah, K., et al. Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes. BMC Cancer 13, 23 (2013
103. Swords, K., Wallen, E. M.,&Pruthi, R. S. The impact of race on prostate cancer detection and choice of treatment in men undergoing a contemporary extended biopsy approach. Urol. Oncol. 28, 280-284 (2010
104. Johnstone, P. A., et al. Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-Access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. Radiology 225, 420-426 (2002
105. Connell, P. P., et al. Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J. Clin. Oncol. 19, 54-61 (2001
106. Rosser, C. J., et al. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J. Natl Med. Assoc. 96, 939-944 (2004
107. Shah, C., et al. Differences in disease presentation, treatment outcomes, and toxicities in African American patients treated with radiation therapy for prostate cancer. Am. J. Clin. Oncol. 35, 566-571 (2012
108. Roach, M., et al. Race and survival of men treated for prostate cancer on radiation therapy oncology group Phase III randomized trials. J. Urol. 169, 245-250 (2003
109. Optenberg, S. A., et al. Race, treatment, and long-Term survival from prostate cancer in an equal-Access medical care delivery system. JAMA 274, 1599-1605 (1995
110. Yamoah, K., Stone, N.,&Stock, R. Impact of race on biochemical disease recurrence after prostate brachytherapy. Cancer 117, 5589-5600 (2011
111. Winkfield, K. M., et al. Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 81, e345-e350 (2011
112. Lowrance, W. T., et al. Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int. 109, 1309-1314 (2012
113. Lu Yao, G., Moore, D. F., Oleynick, J., Dipaola, R. S.,&Yao, S. L. Use of hormonal therapy in men with metastatic prostate cancer. J. Urol. 176, 526-531 (2006
114. Thatai, L. C., Banerjee, M., Lai, Z.,&Vaishampayan, U. Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer. Urology 64, 738-743 (2004
115. Halabi, S., et al. Impact of race on survival in men with metastatic hormone-refractory prostate cancer. Urology 64, 212-217 (2004
116. Bergman, J., et al. Hospice use and high-intensity care in men dying of prostate cancer. Arch. Intern. Med. 171, 204-210 (2011
117. Brassell, S. A., Elsamanoudi, S. I., Cullen, J., Williams, M. E.,&McLeod, D. G. Health-related quality of life for men with prostate cancer-An evaluation of outcomes 12-24 months after treatment. Urol. Oncol. 31, 1504-1510 (2013
118. Aizer, A. A., et al. Lack of reduction in racial disparities in cancer-specific mortality over a 20 year period. Cancer 120, 1532-1539 (2014
119. Moul, J W. Active surveillance for African-American men with prostate cancer: of course! Oncology (Williston Park) 82, 84-85 (2014
120. Lee, E. W., Marien, T., Laze, J., Agalliu, I.,&Lepor, H. Comparison of health-related quality-of life outcomes for African-American and Caucasian-American men after radical prostatectomy. BJU Int. 110, 1129-1133 (2012
121. Hayn, M. H., et al. Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer. Cancer 117, 4651-4658 (2011
122. Stanford, J. L., et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 283, 354-360 (2000
123. Bryant, C., et al. Does race influence health-related quality of life and toxicity following proton therapy for prostate cancer?. Am. J. Clin. Oncol. http://dx.doi.org/10.1097/COC.0000000000000050 (2014
124. Sevilla, C., Maliski, S. L., Kwan, L., Connor, S. E.,&Litwin, M. S. Long-Term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy. Prostate Cancer Prostat. Dis. 15, 237-243 (2012